1. State Key Laboratory of Experimental Hematology, Department of Clinical Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China;
2. Shanghai Institute of Hematology, Shanghai Ruijin Hospital, Shanghai, China;
3. Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Italy;
4. Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang Province, China;
5. Institute of Hematology, Wuhan Union Hospital, Tongji Medical College, Wuhan Hubei, China;
6. Department of Hematology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou Guangdong, China;
7. Department of Hematology, Jiangsu Province People’s Hospital, Nan Jing, China;
8. Department of Hematology, Nanfang Hospital, Guangzhou Southern Medical University, Guangzhou Guangdong, China;
9. Department of Hematology, West China Hospital of Sichuan University, Chengdu Sichuan, China;
10. Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China;
11. Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai, China;
12. Department of Hematology, Qilu Hospital, Shandong University, Jinan, China;
13. Novartis Pharma AG, Basel, Switzerland;
14. Novartis Pharmaceuticals Corporation, East Hanover, NJ;
15. Beijing Novartis Pharma Company, Limited, Beijing, China;
16. Department of Hematology-Oncology, and the Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy; and
17. Peking University People’s Hospital and Institute of Hematology, Beijing, China